Develops oral small-molecule drugs targeting G protein-coupled receptors using a proprietary structural platform.
Develops oral small-molecule drugs targeting G protein-coupled receptors using a proprietary structural platform.
Has no approved drug; income is upfront and milestone payments from pharma partners such as Otsuka, plus money raised from investors. Its platform keeps receptor proteins in their working shape outside living cells so they can be studied and screened, and partners pay to use it on their chosen targets.
Moat: narrow (IP / patents, process know-how). Proprietary native GPCR structural platform enables drugging previously undruggable receptor targets.
Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 130
Size Septerna (SEPN) is a United States Health Care company (Biotechnology) with a market value of $1.88B, the 1810th largest of 3,085 United States companies the cockpit tracks. Shares closed at $39.45 on 18 Nov 2026.
Performance Over six months the shares gained 40.8%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue grew 336.7% over the last twelve months (peer median +5.5%); the operating margin is -76.2% (peer median -29.7%).
Valuation It trades at 14.7× enterprise value to sales against a peer median of 12.6× (7th most expensive of 15).
Short interest Short interest is 7.2% of the free float (30 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $96.3M | $46.0M | $1.07M | $151,000 | $0 |
| Revenue growth | — | +4,175% | +612% | — | — |
| Gross profit | $94.6M | $44.3M | -$326,000 | -$697,000 | -$577,000 |
| EBITDA | -$71.7M | -$79.2M | -$79.4M | -$44.7M | -$27.4M |
| Net income | -$59.0M | -$48.9M | -$71.8M | $567,000 | -$27.7M |
| Free cash flow | -$77.6M | $110M | -$69.6M | -$41.6M | -$24.6M |
| Capital expenditure | $1.02M | $518,000 | $2.10M | $2.88M | $1.29M |
| Total debt | $22.0M | $23.6M | $25.5M | $12.6M | $710,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Septerna SEPN | $1.88B | +41% | +337% | -76% | 14.7× | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | $1.24B | -53% | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | $458M | -15% | +80% | -32% | 2.2× | n/a |
| Crinetics Pharmaceuticals CRNX | n/a | +109% | n/a | n/a | n/a | n/a |
| Viking Therapeutics VKTX | $3.34B | -9% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SEPN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -6.2% | 9th highest of 20 |
| 6-month return | +40.8% | -4.7% | 6th highest of 19 |
| Distance from 52-week high | -26.0% | -34.3% | 7th highest of 21 |
| Revenue growth (TTM) | +336.7% | +5.5% | highest of 15 |
| Operating margin | -76.2% | -29.7% | 6th lowest of 15 |
| EV / Sales | 14.7× | 12.6× | 7th most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |